Cardiovascular magnetic resonance in systemic hypertension

Journal of Cardiovascular Magnetic Resonance

Volumn 14, Issue 1, 2012, Pages

  MacEira, Alicia M ^a   Mohiaddin, Raad H ^b,c  

^a Hospital General Universitario Avda   (Spain)

^b ROYAL BROMPTON AND HAREFIELD NHS FOUNDATION TRUST   (United Kingdom)

^c NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN TYPE 1; COLLAGEN TYPE 3; GADOLINIUM; NUCLEAR MAGNETIC RESONANCE IMAGING AGENT;

AORTA COARCTATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MAGNETIC RESONANCE; CARDIOVASCULAR SYSTEM; CLINICAL RESEARCH; CONTRAST ENHANCEMENT; CORONARY ARTERY DISEASE; CUSHING SYNDROME; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIFFERENTIAL DIAGNOSIS; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAM; GEOMETRY; HEART HEMODYNAMICS; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE VOLUME; HEART MUSCLE FIBROSIS; HUMAN; HYPERTENSION; HYPERTROPHIC CARDIOMYOPATHY; M MODE ECHOCARDIOGRAPHY; MAGNETIC RESONANCE ANGIOGRAPHY; MORTALITY; PATHOPHYSIOLOGY; PERIPHERAL VASCULAR DISEASE; PHEOCHROMOCYTOMA; PRACTICE GUIDELINE; PREDICTIVE VALUE; PRIMARY HYPERALDOSTERONISM; PRIORITY JOURNAL; RENOVASCULAR DISEASE; REVIEW; SENSITIVITY AND SPECIFICITY; SYSTOLIC BLOOD PRESSURE; THREE DIMENSIONAL ECHOCARDIOGRAPHY; THREE DIMENSIONAL IMAGING; ARTICLE; FIBROSIS; HEART MUSCLE; HEART VENTRICLE; HEART VENTRICLE FUNCTION; HEMODYNAMICS; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; PROGNOSIS; RISK ASSESSMENT; RISK FACTOR;

CARDIOVASCULAR DISEASES; FIBROSIS; HEART VENTRICLES; HEMODYNAMICS; HUMANS; HYPERTENSION; MAGNETIC RESONANCE IMAGING; MYOCARDIUM; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS; VENTRICULAR FUNCTION;

EID: 84862118510     PISSN: 10976647     EISSN: 1532429X     Source Type: Journal    
DOI: 10.1186/1532-429X-14-28     Document Type: Review

References (118)

1. Global burden of hypertension: analysis of worldwide data. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J, Lancet 2005 365 217 223 15652604 (Pubitemid 40138015)
2. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. Levy D, Garrison R, Savage D, Kannel W, Castelli W, N Engl J Med 1990 322 1561 1566 10.1056/ NEJM199005313222203 2139921 (Pubitemid 20176696)
3. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R, Lancet 2002 360 1903 1913 12493255 (Pubitemid 35472129)
4. Atrial fibrillation in hypertension: predictors and outcome. Verdecchia P, Reboldi G, Gattobigio R, Bentivoglio M, Borgioni C, Angeli F, Carluccio E, Sardone MG, Porcellati C, Hypertension 2003 41 218 223 10.1161/01.HYP. 0000052830.02773.E4 12574085 (Pubitemid 36204892)
5. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, Jones DW, Materson BJ, Oparil S, Wright JT, Roccella EJ, Hypertension 2003 42 1206 1252 10.1161/01.HYP.0000107251.49515.c2 14656957 (Pubitemid 37553153)
6. Guidelines for the management of arterial Hipertensián. The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC), European Heart Journal 2007 28 1462 1536 17562668
7. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. Mancia G, Laurent S, Agabiti-Rosei E, Ambrosioni E, Burnier M, Caulfield MJ, Cifkova R, Clément D, Coca A, Dominiczak A, Erdine S, Fagard R, Farsang C, Grassi G, Haller H, Heagerty A, Kjeldsen SE, Kiowski W, Mallion JM, Manolis A, Narkiewicz K, Nilsson P, Olsen MH, Rahn KH, Redon J, Rodicio J, Ruilope L, Schmieder RE, Struijker-Boudier HA, van Zwieten PA, Viigimaa M, Zanchetti A, Journal of Hypertension 2009 27 2121 2158 10.1097/HJH.0b013e328333146d 19838131
8. ACCF/ACR/AHA/NASCI/SCMR 2010 expert consensus document on cardiovascular magnetic resonance: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents. American College of Cardiology Foundation Task Force on Expert Consensus Documents, Hundley WG, Bluemke DA, Finn JP, Flamm SD, Fogel MA, Friedrich MG, Ho VB, Jerosch-Herold M, Kramer CM, Manning WJ, Patel M, Pohost GM, Stillman AE, White RD, Woodard PK, J Am Coll Cardiol 2010 55 2614 2662 10.1016/j.jacc.2009.11.011 20513610
9. The prognostic role of left ventricular hypertrophy in patients with or without coronary artery disease. Ghali J, Liao Y, Simmons B, Castaner A, Cao G, Cooper R, Ann Intern Med 1992 117 831 836 1416558
10. Significance of left ventricular hypertrophy in cardiovascular morbidity and mortality. Kaplinsky E, Cardiovasc Drugs Ther 1994 8 549 556 10.1007/BF00877223 7841088 (Pubitemid 24347240)
11. Left ventricular hypertrophy influences cardiac prognosis in patients undergoing dobutamine cardiac stress testing. Charoenpanichkit C, Morgan TM, Hamilton CA, Wallace EL, Robinson K, Ntim WO, Hundley WG, Circ Cardiovasc Imaging 2010 3 392 397 10.1161/CIRCIMAGING.109.912071 20442370
12. The ventricular complex in left ventricular hypertrophy as obtained by unipolar precordial and limb leads. Sokolow M, Lyon TP, Am Heart J 1949 37 161 186 10.1016/0002-8703(49)90562-1 18107386
13. A point-score system for the ECG diagnosis of left ventricular hypertrophy. Romhilt D, Estes EJ, Am Heart J 1968 75 752 758 10.1016/0002-8703(68)90035-5 4231231
14. Accuracy of echocardiography versus electrocardiography in detecting left ventricular hypertrophy: comparison with postmortem mass measurements. Woythaler J, Singer S, Kwan O, Meltzer R, Reubner B, Bommer W, DeMaria A, J Am Coll Cardiol 1983 2 305 311 10.1016/S0735-1097(83)80167-3 6223063 (Pubitemid 13078796)
15. New gender-specific partition values for ECG criteria of left ventricular hypertrophy: recalibration against cardiac MRI. Alfakih K, Walters K, Jones T, Ridgway J, Hall AS, Sivananthan M, Hypertension 2004 44 175 179 10.1161/01.HYP.0000135249.66192.30 15226274 (Pubitemid 39014235)
16. Inter-study variability in left ventricular mass measurement: comparison between M-mode echocardiography and MRI. Germain P, Roul G, Kastler B, Mossard J, Bareiss P, Sacrez A, Eur Heart J 1992 13 1011 1019 1387084
17. Left ventricular mass: reliability of M-mode and 2-dimensional echocardiographic formulas. Myerson SG, Montgomery HE, World MJ, Pennell DJ, Hypertension 2002 40 673 678 10.1161/01.HYP.0000036401.99908.DB 12411461 (Pubitemid 35278604)
18. Transesophageal 3-dimensional echocardiography: in vivo determination of left ventricular mass in comparison with magnetic resonance imaging. Kuhl H, Bucker A, Franke A, Maul S, Nolte-Ernsting C, Reineke T, Hoffmann R, Günther RW, Hanrath P, J Am Soc Echocardiogr 2000 13 205 215 10708469 (Pubitemid 30159914)
19. Comparison of interstudy reproducibility of cardiovascular magnetic resonance with two-dimensional echocardiography in normal subjects and in patients with heart failure or left ventricular hypertrophy. Grothues F, Smith GC, Moon JC, Bellenger NG, Collins P, Klein HU, Pennell DJ, Am J Cardiol 2002 90 29 34 10.1016/S0002-9149(02)02381-0 12088775 (Pubitemid 34671198)
20. Normalized left ventricular systolic and diastolic function by steady state free precession cardiovascular magnetic resonance. Maceira AM, Prasad SK, Khan M, Pennell DJ, J Cardiovasc Magn Reson 2006 8 417 426 10.1080/ 10976640600572889 16755827
21. Reduction in sample size for studies of remodeling in heart failure by the use of cardiovascular magnetic resonance. Bellenger NG, Davies LC, Francis JM, Coats AJ, Pennell DJ, J Cardiovasc Magn Reson 2000 2 271 278 10.3109/10976640009148691 11545126 (Pubitemid 32048395)
22. Left ventricular mass: allometric scaling, normative values, effect of obesity, and prognostic performance. Chirinos JA, Segers P, De Buyzere ML, Kronmal RA, Raja MW, De Bacquer D, Claessens T, Gillebert TC, St John-Sutton M, Rietzschel ER, Hypertension 2010 56 91 98 10.1161/HYPERTENSIONAHA.110.150250 20458004
23. Hypertrophic cardiomyopathy phenotype revisited after 50 years with cardiovascular magnetic resonance. Maron MS, Maron BJ, Harrigan C, Buros J, Gibson CM, Olivotto I, Biller L, Lesser JR, Udelson JE, Manning WJ, Appelbaum E, J Am Coll Cardiol 2009 54 220 228 10.1016/j.jacc.2009.05.006 19589434
24. A 4-tiered classification of left ventricular hypertrophy based on left ventricular geometry: the Dallas heart study. Khouri MG, Peshock RM, Ayers CR, De Lemos JA, Drazner MH, Circ Cardiovasc Imaging 2010 3 164 171 10.1161/CIRCIMAGING.109.883652 20061518
25. Left ventricular geometric patterns in the Jackson cohort of the Atherosclerotic Risk in Communities (ARIC) Study: clinical correlates and influences on systolic and diastolic dysfunction. Fox ER, Taylor J, Taylor H, Han H, Samdarshi T, Arnett D, Myerson M, Am Heart J 2007 153 238 244 10.1016/j.ahj.2006.09.013 17239683 (Pubitemid 46099033)
26. Left ventricular concentric geometry during treatment adversely affects cardiovascular prognosis in hypertensive patients. Muiesan ML, Salvetti M, Monteduro C, Bonzi B, Paini A, Viola S, Poisa P, Rizzoni D, Castellano M, Agabiti-Rosei E, Hypertension 2004 43 731 738 10.1161/01.HYP.0000121223.44837.de 15007041 (Pubitemid 38405579)
27. Left ventricular mass and ventricular remodeling among Hispanic subgroups compared with non-Hispanic blacks and whites: MESA (Multi-ethnic Study of Atherosclerosis). Rodriguez CJ, Diez-Roux AV, Moran A, Jin Z, Kronmal RA, Lima J, Homma S, Bluemke DA, Barr RG, J Am Coll Cardiol 2010 55 234 242 10.1016/j.jacc.2009.08.046 20117402
28. Midwall left ventricular mechanics. An independent predictor of cardiovascular risk in arterial hypertension. De Simone G, Devereux RB, Koren MJ, Mensah GA, Casale PN, Laraqh JH, Circulation 1996 93 259 265 8548897 (Pubitemid 26031483)
29. Short-axis epicardial volume change is a measure of cardiac left ventricular short-axis function, which is independent of myocardial wall thickness. Ugander M, Carlsson M, Arheden H, Am J Physiol Heart Circ Physiol 2010 298 530 H535 10.1152/ajpheart.00153.2009 19933422
30. Measurement of left ventricular velocities: phase contrast MRI velocity mapping versus tissue-doppler-ultrasound in healthy volunteers. Jung B, Schneider B, Markl M, Saurbier B, Geibel A, Hennig J, J Cardiovasc Magn Reson 2004 6 777 783 10.1081/JCMR-200036116 15646880 (Pubitemid 40041281)
31. Early hypertension is associated with reduced regional cardiac function, insulin resistance, epicardial, and visceral fat. Sironi AM, Pingitore A, Ghione S, De Marchi D, Scattini B, Positano V, Muscelli E, Ciociaro D, Lombardi M, Ferrannini E, Gastaldelli A, Hypertension 2008 51 282 288 10.1161/ HYPERTENSIONAHA.107.098640 18172058 (Pubitemid 351159940)
32. Marked regional left ventricular heterogeneity in hypertensive left ventricular hypertrophy patients: a losartan intervention for endpoint reduction in hypertension (LIFE) cardiovascular magnetic resonance and echocardiographic substudy. Biedeman RW, Doyle M, Young AA, Devereux RB, Kortright E, Perry G, Bella JN, Oparil S, Calhoun D, Pohost GM, DellItalia LJ, Hypertension 2008 52 279 286 10.1161/HYPERTENSIONAHA.108.109819 18606908
33. Clinical indications for cardiovascular magnetic resonance (CMR): Consensus panel report. Pennell DJ, Sechtem U, Higgins CB, Manning WJ, Pohost GM, Rademakers FE, van Rossum AC, Shaw LJ, Eur Heart J 2004 25 1940 1965 10.1016/j.ehj.2004.06.040 15522474 (Pubitemid 39452612)
34. Is cardiovascular remodeling in patients with essential hypertension related to more than high blood pressure? A LIFE substudy. Losartan Intervention For Endpoint-Reduction in Hypertension. Olsen MH, Wachtell K, Hermann KL, Frandsen E, Dige-Petersen H, Rokkedal J, Devereux R, Ibsen H, Am Heart J 2002 144 530 537 10.1067/mhj.2002.124863 12228792
35. TELMAR Investigators. Reduction (TELMAR) as assessed by magnetic resonance imaging in patients with mild-to-moderate hypertension-a prospective, randomised, double-blind comparison of telmisartan with metoprolol over a period of six months rationale and study design. Friedrich MG, Dahlof B, Sechtem U, Unger T, Knecht M, Dietz R, J Renin Angiotensin Aldosterone Syst 2003 4 234 243 10.3317/jraas.2003.038 14689371 (Pubitemid 38008175)
36. Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study. Pitt B, Reichek N, Willenbrock R, Zannad F, Phillips RA, Roniker B, Kleiman J, Krause J, Krause S, Burns D, Williams GH, Circulation 2003 108 1831 1838 10.1161/01.CIR.0000091405.00772.6E 14517164 (Pubitemid 37296092)
37. Magnetic resonance imaging left ventricular mass reduction with fixed-dose angiotensin-converting enzyme inhibitor-based regimens in patients with high-risk hypertension. Reichek N, Devereux RB, Rocha RA, Hilkert R, Hall D, Purkayastha D, Pitt B, Hypertension 2009 54 731 737 10.1161/HYPERTENSIONAHA. 109.130641 19687350
38. Aliskiren in Left Ventricular Hypertrophy (ALLAY) Trial Investigators. Effect of the direct Renin inhibitor aliskiren, the Angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy. Solomon SD, Appelbaum E, Manning WJ, Verma A, Berglund T, Lukashevich V, Cherif Papst C, Smith BA, Dahlöf B, Circulation 2009 119 530 537 10.1161/CIRCULATIONAHA.108.826214 19153265
39. Cardiovascular magnetic resonance in cardiac amyloidosis. Maceira AM, Joshi J, Prasad SK, Moon JC, Perugini E, Harding I, Sheppard MN, Poole-Wilson PA, Hawkins PN, Pennell DJ, Circulation 2005 111 186 193 10.1161/01.CIR. 0000152819.97857.9D 15630027 (Pubitemid 40139730)
40. Cardiovascular magnetic resonance in clinically suspected cardiac amyloidosis: noninvasive imaging compared to endomyocardial biopsy. Vogelsberg H, Mahrholdt H, Deluigi CC, Yilmaz Z, Kispert EM, Greulich S, Klingel K, Kandolf R, Sechtem U, J Am Coll Cardiol 2008 51 1022 1030 10.1016/j.jacc.2007.10.049 18325442 (Pubitemid 351318125)
41. Usefulness of magnetic resonance imaging to distinguish hypertensive and hypertrophic cardiomyopathy. Puntmann VO, Jahnke C, Gebker R, Schnackenburg B, Fox KF, Fleck E, Paetsch I, Am J Cardiol 2010 106 1016 1022 10.1016/j.amjcard. 2010.05.036 20854967
42. Differentiation of athletes heart from pathological forms of cardiac hypertrophy by means of geometric indices derived from cardiovascular magnetic resonance. Petersen SE, Selvanayagam JB, Francis JM, Myerson SG, Wiesmann F, Robson MD, Ostman-Smith I, Casadei B, Watkins H, Neubauer S, J Cardiovasc Magn Reson 2005 7 551 558 10.1081/JCMR-200060631 15959967 (Pubitemid 40770332)
43. Clinical aspects of hypertensive myocardial fibrosis. Díez J, Lápez B, González A, Querejeta R, Curr Opin Cardiol 2001 16 328 335 10.1097/00001573-200111000-00003 11704701 (Pubitemid 33135220)
44. Noninvasive detection of fibrosis applying contrast-enhanced cardiac magnetic resonance in different forms of left ventricular hypertrophy relation to remodeling. Rudolph A, Abdel-Aty H, Bohl S, Boyé P, Zagrosek A, Dietz R, Schulz-Menger J, J Am Coll Cardiol 2009 53 284 291 10.1016/j.jacc.2008.08.064 19147047
45. Assessment of myocardial fibrosis with cardiovascular magnetic resonance. Mewton M, Liu CY, Croisille P, Bluemke D, Lima J, J Am Coll Cardiol 2011 57 891 903 10.1016/j.jacc.2010.11.013 21329834
46. Mechanisms of cardiac fibrosis in hypertension. Díez M, J Clin Hypertens 2007 9 546 550 10.1111/j.1524-6175.2007.06626.x
47. Serum carboxy-terminal propeptide of procollagen type I is a marker of myocardial fibrosis in hypertensive heart disease. Querejeta R, Varo N, Lápez B, Larman M, Artĩano E, Etayo JC, Martínez Ubago JL, Gutiérrez-Stampa M, Emparanza JI, Gil MJ, Monreal I, Mindán JP, Díez J, Circulation 2000 101 1729 1735 10758057 (Pubitemid 30196635)
48. Different effects of antihypertensive therapies based on losartan or atenolol on ultrasound and biochemical markers of myocardial fibrosis: results of a randomized trial. Ciulla MM, Paliotti R, Esposito A, Diez J, Lopez B, Dahlof B, Nicholls MG, Smith RD, Gilles L, Magrini F, Zanchetti A, Circulation 2004 110 552 557 10.1161/01.CIR.0000137118.47943.5C 15277331 (Pubitemid 39031172)
49. Estimation of left ventricular operating stiffness from Doppler early filling deceleration time in humans. Garcia MJ, Firstenberg MS, Greenberg NL, Smedira N, Rodriguez L, Prior D, Thomas JD, Am J Physiol Heart Circ Physiol 2001 280 554 H561 11158951
50. Ultrasonic backscatter and serum marker of cardiac fibrosis in hypertensives. Maceira AM, Barba J, Varo N, Beloqui O, Díez J, Hypertension 2002 39 923 928 10.1161/01.HYP.0000014616.48920.8F 11967251 (Pubitemid 34437551)
51. Ultrasonic backscatter and diastolic function in hypertensive patients. Maceira AM, Barba J, Beloqui O, Díez J, Hypertension 2002 40 239 243 10.1161/01.HYP.0000030154.90042.4C 12215460 (Pubitemid 35006704)
52. The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction. Kim RJ, Wu E, Rafael A, Chen EL, Parker MA, Simonetti O, Klocke FJ, Bonow RO, Judd RM, N Engl J Med 2000 343 1445 1453 10.1056/NEJM200011163432003 11078769
53. The histologic basis of late gadolinium enhancement cardiovascular magnetic resonance in hypertrophic cardiomyopathy. Moon JCC, Reed E, Sheppard MN, Elkington AG, SiewYen H, Burke M, Petro M, Pennell DJ, J Am Coll Cardiol 2004 43 2260 2264 10.1016/j.jacc.2004.03.035 15193690 (Pubitemid 38757595)
54. Prognostic value of late gadolinium enhancement in hypertensive patients with known or suspected coronary artery disease. Krittayaphong R, Boonyasirinant T, Chaithiraphan V, Maneesai A, Saiviroonporn P, Nakyen S, Thanapiboonpol P, Yindeengam A, Udompanturak S, Int J Cardiovasc Imaging 2010 26 Suppl 1 123 131 20049536
55. Myocardial delayed contrast enhancement in patients with arterial hypertension: initial results of cardiac MRI. Andersen K, Hennersdorf M, Cohnen M, Blondin D, Mödder U, Poll LW, Eur J Radiol 2009 71 75 81 10.1016/j.ejrad.2008.03.009 18434065
56. Measurement of gadopentetate dimeglumine partition coefficient in human myocardium in vivo: normal distribution and elevation in acute and chronic myocardial infarction. Flacke SJ, Fischer SE, Lorenz CH, Radiology 2001 218 703 710 11230643 (Pubitemid 32172551)
57. Cardiac magnetic resonance imaging of myocardial contrast uptake and blood flow in patients affected with idiopatic or dilated cardiomyopathy. Jerosch-Herold M, Sheridan DC, Kushner JD, Nauman D, Burgess D, Dutton D, Alharethi R, Li D, Hershberger RE, Am J Physiol Heart Circ Physiol 2008 295 1234 H1242 10.1152/ajpheart.00429.2008 18660445
58. Dysfunction in congenital heart disease. Broberg CS, Chugh SS, Conklin C, Sahn DJ, Jerosch-Herold M, Circ Cardiovasc Imaging 2010 3 727 734 10.1161/CIRCIMAGING.108.842096 20855860
59. Myocardial T1 mapping, application to patients with acute and chronic myocardial infarction. Messroghli DR, Walters K, Plein S, Sparrow P, Friedrich MG, Ridgway JP, Sivananthan MU, Magn Reson Med 2007 58 34 40 10.1002/mrm.21272 17659622 (Pubitemid 47229915)
60. Extracellular volume imaging by magnetic resonance imaging provides insights into overt and sub-clinical myocardial pathology. Ugander M, Oki AJ, Hsu LY, Kellman P, Greiser A, Aletras AH, Sibley CT, Chen MY, Bandettini WP, Arai AE, Eur Heart J 2012 [Epub ahead of print] 10.1093/eurheartj/ehr481
61. Myocardial T1 and Extracellular Volume Fraction Mapping at 3 Tesla. Lee JJ, Liu S, Nacif MS, Ugander M, Han J, Kawel N, Sibley CT, Kellman P, Arai AE, Bluemke DA, J Cardiovasc Magn Reson 2011 13 75 10.1186/1532-429X-13-75 22123333
62. Shortened Modified Look-Locker Inversion recovery (ShMOLLI) for clinical myocardial T1- mapping at 1.5 and 3 T within a 9 heartbeat breathhold. Piechnik SK, Ferreira VM, DallArmellina E, Cochlin LE, Greiser A, Neubauer S, Robson MD, et al. Journal of Cardiovascular Magnetic Resonance 2010 12 69 80 10.1186/1532-429X-12-69 21092095
63. Histological validation of ShMOLLI equilibrium contrast CMR for the measurement of diffuse myocardial fibrosis. White SK, Piechnik SK, Neubauer S, Robson MD, Moon J, Journal of Cardiovascular Magnetic Resonance 2012 14 Suppl 1 111 10.1186/1532-429X-14-S1-O111
64. Systolic and diastolic heart failure in the community. Bursi F, Weston SA, Redfield MM, Jacobsen SJ, Pakhomov S, Nkomo VT, Meverden RA, Roger VL, JAMA 2006 296 2209 2216 10.1001/jama.296.18.2209 17090767 (Pubitemid 44708051)
65. Automated segmentation of routine clinical cardiac magnetic resonance imaging for assessment of left ventricular diastolic dysfunction. Kawaji K, Codella NC, Prince MR, Chu CW, Shakoor A, LaBounty TM, Min JK, Swaminathan RV, Devereux RB, Wang Y, Weinsaft JW, Circ Cardiovasc Imaging 2009 2 476 484 10.1161/CIRCIMAGING.109.879304 19920046
66. MeRGE Heart Failure Collaborators. Independent relationship of left atrial size and mortality in patients with heart failure: an individual patient meta-analysis of longitudinal data (MeRGE Heart Failure). Rossi A, Temporelli PL, Quintana M, Dini FL, Ghio S, Hillis GS, Klein AL, Marsan NA, Prior DL, Yu CM, Poppe KK, Doughty RN, Whalley GA, Eur J Heart Fail 2009 11 929 936 10.1093/eurjhf/hfp112 19789395
67. Role of left atrial size in risk stratification and prognosis of patients undergoing stress echocardiography. Bangalore S, Yao SS, Chaudhry FA, J Am Coll Cardiol 2007 50 1254 1262 10.1016/j.jacc.2007.06.025 17888843 (Pubitemid 47405137)
68. Atrial and ventricular volume and function in persistent and permanent atrial fibrillation, a magnetic resonance imaging study. Therkelsen SK, Groenning BA, Svendsen JH, Jensen GB, J Cardiovasc Magn Reson 2005 7 465 473 10.1081/JCMR-200053618 15881530 (Pubitemid 40575740)
69. Reference left atrial dimensions and volumes by steady state free precession cardiovascular magnetic resonance. Maceira A, Cosín-Sales J, Roughton M, Prasad SK, Pennell DJ, J Cardiovasc Magn Reson 2010 12 65 72 10.1186/1532-429X-12-65 21070636
70. Changes in risk factors and the decline in mortality from cardiovascular disease. The Framingham Heart Study. Sytkowski PA, Kannel WB, DAgostino RB, N Engl J Med 1990 322 1635 1641 10.1056/NEJM199006073222304 2288563 (Pubitemid 20171587)
71. MRFIT Research Group. Blood pressure and risk of death from external causes among men screened for the Multiple Risk Factor Intervention Trial. Terry PD, Abramson JL, Neaton JD, Am J Epidemiol 2007 165 294 301 17098820 (Pubitemid 46174753)
72. Hypertension and left ventricular hypertrophy are associated with impaired endothelium mediated relaxation in human coronary resistance vessels. Treasure CB, Klein JL, Vita JA, Manoukian SV, Renwick GH, Selwyn AP, Ganz P, Alexander RW, Circulation 1993 87 86 93 8419028 (Pubitemid 23019338)
73. Detection of cardiac small vessel disease by adenosine-stress magnetic resonance. Bernhardt P, Levenson B, Albrecht A, Engels T, Strohm O, Int J Cardiol 2007 121 261 266 10.1016/j.ijcard.2006.11.008 17196688 (Pubitemid 47445793)
74. Comprehensive adenosine stress perfusion MRI defines the etiology of chest pain in the emergency room: Comparison with nuclear stress test. Vogel-Claussen J, Skrok J, Dombroski D, Shea SM, Shapiro EP, Bohlman M, Lorenz CH, Lima JA, Bluemke DA, J Magn Reson Imaging 2009 30 753 762 10.1002/jmri.21899 19787721
75. Diagnostic value of perfusion cardiovascular magnetic resonance in patients with angina pectoris but normal coronary angiograms assessed by intracoronary acetylcholine testing. Yilmaz A, Athanasiadis A, Mahrholdt H, Voehringer M, Ong P, Hill S, Kispert EM, Seebo M, Sechtem U, Heart 2010 96 372 379 10.1136/hrt.2009.174367 19934103
76. Cardiovascular outcome of patients with abnormal coronary vasomotion and normal coronary arteriography is worse in type 2 diabetes mellitus than in arterial hypertension: a 10 year follow-up study. Nitenberg A, Pham I, Antony I, Valensi P, Attali JR, Chemla D, Atherosclerosis 2005 183 113 120 10.1016/j.atherosclerosis.2005.02.030 16216594 (Pubitemid 41416829)
77. MR-IMPACT: comparison of perfusion-cardiac magnetic resonance with single-photon emission computed tomography for the detection of coronary artery disease in a multicentre, multivendor, randomized trial. Schwitter J, Wacker C, van Rossum A, Lombardi M, Al-Saadi N, Ahlstrom H, Dill T, Larsson HB, Flamm S, Marquardt M, Johansson L, Eur Heart J 2008 29 480 489 10.1093/eurheartj/ehm617 18208849 (Pubitemid 351264187)
78. Assessment of myocardial perfusion in coronary artery disease by magnetic resonance: a comparison with positron emission tomography and coronary angiography. Schwitter J, Nanz D, Kneifel S, Bertschinger K, Buchi M, Knusel PR, Marincek B, Luscher TF, von Schulthess GK, Circulation 2001 103 2230 2235 11342469 (Pubitemid 32433710)
79. Cardiovascular magnetic resonance and single-photon emission computed tomography for diagnosis of coronary heart disease (CE-MARC): a prospective trial. Greenwood JP, Maredia N, Younger JF, Brown JM, Nixon J, Everett CC, Bijsterveld P, Ridgway JP, Radjenovic A, Dickinson CJ, Ball SG, Plein S, Lancet 2012 379 453 460 10.1016/S0140-6736(11)61335-4 22196944
80. Assessment of non-ST-segment elevation acute coronary syndromes with cardiac magnetic resonance imaging. Plein S, Greenwood JP, Ridgway JP, Cranny G, Ball SG, Sivananthan MU, J Am Coll Cardiol 2004 44 2173 2181 10.1016/j.jacc.2004.08.056 15582315 (Pubitemid 39576037)
81. Relationship of MRI delayed contrast enhancement to irreversible injury, infarct age, and contractile function. Kim RJ, Fieno DS, Parrish TB, Harris K, Chen EL, Simonetti O, Bundy J, Finn JP, Klocke FJ, Judd RM, Circulation 1999 100 1992 2002 10556226 (Pubitemid 29529292)
82. Relation of aortic wall thickness and distensibility to cardiovascular risk factors (from the Multi-Ethnic Study of Atherosclerosis [MESA]). Malayeri AA, Natori S, Bahrami H, Bertoni AG, Kronmal R, Lima JA, Bluemke DA, Am J Cardiol 2008 102 491 496 10.1016/j.amjcard.2008.04.010 18678312
83. Reduced ascending aortic strain and distensibility: earliest manifestations of vascular aging in humans. Redheuil A, Yu WC, Wu CO, Mousseaux E, de Cesare A, Yan R, Kachenoura N, Bluemke D, Lima JA, Hypertension 2010 55 319 326 10.1161/HYPERTENSIONAHA.109.141275 20065154
84. Left ventricular hypertrophy, aortic wall thickness, and lifetime predicted risk of cardiovascular disease:the Dallas Heart Study. Gupta S, Berry JD, Ayers CR, Peshock RM, Khera A, de Lemos JA, Patel PC, Markham DW, Drazner MH, JACC Cardiovasc Imaging 2010 3 605 613 10.1016/j.jcmg.2010.03.005 20541716
85. Cardiovascular magnetic resonance parameters of atherosclerotic plaque burden improve discrimination of prior major adverse cardiovascular events. Mani V, Muntner P, Gidding SS, Aguiar SH, El Aidi H, Weinshelbaum KB, Taniguchi H, van der Geest R, Reiber JH, Bansilal S, Farkouh M, Fuster V, Postley JE, Woodward M, Fayad ZA, J Cardiovasc Magn Reson 2009 11 10 10.1186/1532-429X-11-10 19393089
86. Insights into atherosclerosis from invasive and non-invasive imaging studies: Should we treat subclinical atherosclerosis? Santos RD, Nasir K, Atherosclerosis 2009 205 349 356 10.1016/j.atherosclerosis.2008.12.017 19281982
87. Assessment of human atherosclerotic carotid plaque components with multisequence MR imaging: initial experience. Cappendijk VC, Cleutjens KB, Kessels AG, Heeneman S, Schurink GW, Welten RJ, Mess WH, Daemen MJ, van Engelshoven JM, Kooi ME, Radiology 2005 234 487 492 10.1148/radiol.2342032101 15671004 (Pubitemid 40139920)
88. Lipid lowering by simvastatin induces regression of human atherosclerotic lesions: two years follow-up by high-resolution noninvasive magnetic resonance imaging. Corti R, Fuster V, Fayad ZA, Worthley SG, Helft G, Smith D, Weinberger J, Wentzel J, Mizsei G, Mercuri M, Badimon JJ, Circulation 2002 106 2884 2887 10.1161/01.CIR.0000041255.88750.F0 12460866 (Pubitemid 35424736)
89. Glagov remodeling of the atherosclerotic aorta demonstrated by cardiovascular magnetic resonance: the CORDA asymptomatic subject plaque assessment research (CASPAR) project. Mohiaddin RH, Burman ED, Prasad SK, Varghese A, Tan RS, Collins SA, Hughes RL, Gatejouse PD, Jhooti P, Longmore DB, Yang GZ, Firmin DN, Pennell DJ, J Cardiovasc Magn Reson 2004 6 517 525 10.1081/JCMR-120030576 15137336 (Pubitemid 39277123)
90. High-resolution magnetic resonance imaging enhanced with superparamagnetic nanoparticles measures macrophage burden in atherosclerosis. Morishige K, Kacher DF, Libby P, Josephson L, Ganz P, Weissleder R, Aikawa M, Circulation 2010 122 1707 1715 10.1161/CIRCULATIONAHA.109.891804 20937980
91. Classification of human carotid atherosclerotic lesions with in vivo multicontrast magnetic resonance imaging. Cai JM, Hatsukami TS, Ferguson MS, Small R, Polissar NL, Yuan C, Circulation 2002 106 1368 1373 10.1161/01.CIR.0000028591.44554.F9 12221054 (Pubitemid 35013040)
92. Magnetic resonance images lipid, fibrous, calcified, hemorrhagic and thrombotic components of human atherosclerosis in vivo. Toussaint JF, LaMuraglia GM, Southern JF, Fuster V, Kantor HL, Circulation 1996 94 932 938 8790028 (Pubitemid 26292843)
93. Three-dimensional analysis of segmental wall shear stress in the aorta by flow-sensitive four-dimensional-MRI. Frydrychowicz A, Stalder AF, Russe MF, Bock J, Bauer S, Harloff A, Berger A, Langer M, Hennig J, Markl M, J Magn Reson Imaging 2009 30 77 84 10.1002/jmri.21790 19557849
94. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid- Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group, JAMA 2002 288 2981 2997 10.1001/jama.288.23.2981 12479763 (Pubitemid 35471160)
95. Progression of renal artery stenosis in patients undergoing cardiac catheterization. Crowley JJ, Santos RM, Peter RH, Puma JA, Schwab SJ, Phillips HR, Stack RS, Conlon PJ, Am Heart J 1998 136 913 918 10.1016/S0002-8703(98) 70138-3 9812088 (Pubitemid 28506893)
96. Renal-artery stenosis. Safian RD, Textor SC, N Engl J Med 2001 344 431 442 10.1056/NEJM200102083440607 11172181 (Pubitemid 32128677)
97. Severity of renal vascular disease predicts mortality in patients undergoing coronary angiography. Conlon PJ, Little MA, Pieper K, Mark DB, Kidney Int 2001 60 1490 1497 10.1046/j.1523-1755.2001.00953.x 11576364 (Pubitemid 32960044)
98. Revascularization versus Medical Therapy for Renal-Artery Stenosis. The ASTRAL Investigators, N Engl J Med 2009 361 1953 1962 19907042
99. Renal artery stenosis and accessory renal arteries: accuracy of detection and visualization with gadolinium-enhanced breath-hold MR angiography. Bakker J, Beek FJ, Beutler JJ, Hene RJ, de Kort GA, de Lange EE, Moons KG, Mali WP, Radiology 1998 207 497 504 9577501 (Pubitemid 28259069)
100. Diagnostic tests for renal artery stenosis in patients suspected of having renovascular hypertension: a meta-analysis. Vasbinder GB, Nelemans PJ, Kessels AG, Kroon AA, de Leeuw PW, van Engelshoven JM, Ann Intern Med 2001 135 401 411 11560453 (Pubitemid 32845865)
101. Magnetic resonance angiography for the diagnosis of renal artery stenosis: a meta-analysis. Tan KT, van Beek EJ, Brown PW, van Delden OM, Tijssen J, Ramsay LE, Clin Radiol 2002 57 617 624 10.1053/crad.2002.0941 12096862 (Pubitemid 36113582)
102. Nephrogenic systemic fibrosis: risk factors and incidence estimation. Sadowski EA, Bennett LK, Chan MR, Wentland AL, Garrett Al, Garrett RW, Djamali A, Radiology 2007 243 148 157 10.1148/radiol.2431062144 17267695 (Pubitemid 46579705)
103. Hyperaldosteronism among black and white subjects with resistant hypertension. Calhoun DA, Nishizaka MK, Zaman MA, Thakkar RB, Weissmann P, Hypertension 2002 40 892 896 10.1161/01.HYP.0000040261.30455.B6 12468575 (Pubitemid 35434912)
104. Primary hyperaldosteronism (Conn Syndrome): MR imaging findings. Sohaib SA, Peppercorn PD, Allan C, Monson JP, Grossman AB, Besser GM, Reznek RH, Radiology 2000 214 527 531 10671606 (Pubitemid 30077714)
105. Investigating mineralocorticoid hypertension. Nussberger J, J Hypertens 2003 21 Suppl 2 25 S30
106. Left ventricular structural and functional characteristics in Cushings syndrome. Muiesan ML, Lupia M, Salvetti M, Grigoletto C, Sonino N, Boscaro M, Rosei EA, Mantero F, Fallo F, J Am Coll Cardiol 2003 41 2275 2279 10.1016/S0735-1097(03)00493-5 12821259 (Pubitemid 36724279)
107. Hypertension in patients with Cushings disease: pathophysiology, diagnosis, and management. Sacerdote A, Weiss K, Tran T, Rokeya Noor B, McFarlane SI, Curr Hypertens Rep 2005 7 212 218 10.1007/s11906-005-0013-4 15913497 (Pubitemid 40894927)
108. Beningn adrenocortical masses: diagnosis with chemical shift MR imaging. Mitchell DG, Crovello M, Matteucci T, Peterson RO, Miettinen MM, Radiology 1992 185 345 351 1410337
109. Prospective study on the prevalence of secondary hypertension among hypertensive patients visiting a general outpatient clinic in Japan. Omura M, Saito J, Yamaguchi K, Kakuta Y, Nishikawa T, Hypertens Res 2004 27 193 202 10.1291/hypres.27.193 15080378 (Pubitemid 38489081)
110. Increased blood pressure variability in pheochromocytoma compared to essential hypertension patients. Zelinka T, Strauch B, Petrák O, Holaj R, Vranková A, Weisserová H, Pacák K, Widimsk J, J Hypertens 2005 23 2033 2039 10.1097/01.hjh.0000185714.60788.52 16208146 (Pubitemid 41830399)
111. Coarctation of aorta. Katira R, Rathore VS, Lip GY, Singh SP, J Hum Hypertens 1997 11 537 538 10.1038/sj.jhh.1000477 9322837 (Pubitemid 27434784)
112. Coarctation Long-term Assessment (COALA): Significance of arterial hypertension in a cohort of 404 patients up to 27 years after surgical repair of isolated coarctation of the aorta, even in the absence of restenosis and prosthetic material. Hager A, Kanz S, Kaemmerer H, Schreiber C, Hess J, J Thorac Cardiovasc Surg 2007 134 738 745 10.1016/j.jtcvs.2007.04.027 17723827 (Pubitemid 47301960)
113. Role of the renin-angiotensin-aldosterone system in hypertensive children with coarctation of the aorta. Alpert BS, Bain HH, Balfe JW, Kidd BS, Olley PM, Am J Cardiol 1979 43 828 834 10.1016/0002-9149(79)90085-7 425921 (Pubitemid 9150839)
114. Resetting of the cardiopulmonary baroreflex 10 years after surgical repair of coarctation of the aorta. Johnson D, Perrault H, Vobecky SJ, Trudeau F, Dalvin E, Fournier A, et al. Heart 2001 85 318 e325 10.1136/heart.85.3.318
115. Transesophageal echocardiography (TEE) in congenital heart disease with focus on the adult. Miller-Hance WC, Silverman NH, Cardiol Clin 2000 18 861 892 10.1016/S0733-8651(05)70185-5 11236171 (Pubitemid 32187318)
116. Three-dimensional volume rendering with multislice computed tomography in the evaluation of aortic coarctation. Cademartiri F, Nieman K, Raaijmakers RH, Alfieri O, Krestin GP, Ital Heart J 2003 4 286 287 12784784 (Pubitemid 36834106)
117. Is echocardiography or magnetic resonance imaging superior for precoarctation angioplasty evaluation? Mendelsohn AM, Banerjee A, Donnelly LF, Schwartz DC, Cathet Cardiovasc Diagn 1997 42 26 30 10.1002/(SICI)1097- 0304(199709)42:1<26::AID-CCD7>3.0.CO;2-B 9286533 (Pubitemid 27374175)
118. Late magnetic resonance surveillance of repaired coarctation of the aorta. Puranik R, Tsang VT, Puranik S, Jones R, Cullen S, Bonhoeffer P, Hughes ML, Taylor AM, Eur J Cardiothorac Surg 2009 36 91 95 10.1016/j.ejcts.2009.02.056 19410477